Glucagon Antikörper

Produktnummer ABIN7181328

Der Maus Monoklonal Anti-Glucagon-Antikörper wurde für IHC und ELISA validiert. Er ist geeignet, Glucagon in Proben von Human zu detektieren.

Kurzübersicht für Glucagon Antikörper (ABIN7181328)

Target: Glucagon (GCG)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Glucagon Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA

Produktdetails anti-Glucagon Antikörper

Kreuzreaktivität: Human

Aufreinigung: Affinity purified

Immunogen: Synthesized peptide derived from human Glucagon

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu Glucagon

Target: Glucagon (GCG)

Andere Bezeichnung: GCG

Hintergrund:

Background: Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

Edoardo C. Aromataris, J. Physiol., Jun 2006, 573: 611 - 625.
Xiao C. Li, Hypertension, Mar 2006, 47: 580 - 585.
Kirstan A. Vessey, Invest. Ophthalmol. Vis. Sci., Nov 2005, 46: 3922 - 3931.
Xiaosong Ma, Mol. Endocrinol., Jan 2005, 19: 198 - 212.

Aliases: Glicentin, Glicentin-related polypeptide, Oxyntomodulin, Glucagon-like peptide 1(GLP-1), Glucagon-like peptide 1(7-37)

UniProt: P01275

Pathways: Positive Regulation of Peptide Hormone Secretion, Peptide Hormone Metabolism, cAMP Metabolic Process, Regulation of Carbohydrate Metabolic Process, Feeding Behaviour, Negative Regulation of intrinsic apoptotic Signaling